![]() ![]() ![]() This trial was a little different from EMPA-REG in that this trial had about 35% of patients who were just “at high risk”-maybe they had been over 50 or they had diabetes for more than 10 years-whereas 65% actually had a cardiovascular event. Again, this was the second SGLT2 inhibitor to be studied in a large cardiovascular outcomes trial. ![]() John Anderson, MD: In June of 2017 in San Diego, at the American Diabetes Association Scientific Sessions, the CANVAS trial results were released.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |